Brian Nowosielski

Researchers explored a variety of medicinal plants used for skin-related conditions and assessed their efficacy in treating UV-induced skin damage.

Researchers conducted a survey assessing pharmacy students’ perceptions of pharmacist burnout and how that may impact their future career paths.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses the importance of insulin delivery and the common barriers pharmacists face in managing patients’ regimens.

In part 3 of our interview with Iowa State Representative Brett Barker, PharmD, he discusses how legislation at the state level is gradually informing decisions at the federal level.

Researchers investigated the current treatment strategies for atopic dermatitis and how they related to ideas of corticophobia among providers.

Researchers explored the effectiveness of telephonic insulin titration by a clinical pharmacist compared with in-office titration among patients in a medical residency clinic.

Brett Barker, PharmD, state representative in Iowa’s 51st District, joined Drug Topics to discuss significant implications and common misconceptions regarding Iowa’s new PBM bill.

Researchers determined the impact COVID-19 interventions had on Danish children’s incidence of RSV, influenza, and invasive pneumococcal disease.

Brett Barker, PharmD, State Representative in Iowa’s 51st District, discussed Senate File 383 and how it’s intended to impact Iowa pharmacies.

Following his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter caught up with Drug Topics to discuss the pharmacists’ role in diabetes management.

As state-level PBM reform heats up amid dire situations for many retail pharmacies, Walgreens Chief Pharmacy Officer Rick Gates joins Drug Topics to discuss ongoing industry challenges.

In part 3 of our interview with Walgreens Chief Pharmacy Officer Rick Gates, he explores the future of pharmacy practices and how modern use of technologies like AI are becoming commonplace.

Researchers explored patients with type 1 diabetes and overweight or obesity to understand the efficacy and safety of GLP-1s as adjunctive therapies.

In a recap of his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter, RPh, discussed the role of pharmacists in team-based diabetes care.

Walgreens Chief Pharmacy Officer Rick Gates discusses ongoing movement at the state level regarding pharmacy benefit manager reform.

In an abstract presented at the American Diabetes Association 85th Scientific Sessions, researchers tested the effectiveness of an AI-driven program for improving glycemic control.

Jon Easter, RPh, discusses pharmacists’ ability to improve patient engagement in diabetes care following his presentation at the American Diabetes Association’s 85th Scientific Sessions.

Rick Gates, chief pharmacy officer at Walgreens and chairman of the National Association of Chain Drug Stores, discussed the current status of retail pharmacies and the way they are reimbursed.

Jon Easter, RPh, joined Drug Topics to discuss pharmacists’ roles within health care teams following his presentation at the American Diabetes Association’s 85th Scientific Sessions.

With the emergence of increased GLP-1 use and alternative PBM models, Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, joined Drug Topics to discuss current trends in drug benefit design.

Researchers explored the prevalence of obesity-related complications and obesity medication use in US children and young adults with obesity.

Researchers presented an abstract describing current racial disparities in CGM access and wear time to better inform quality improvement efforts.

Pharmaceutical Strategies Group experts joined Drug Topics to discuss the role GLP-1s play in drug benefit design.

Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.

In a retrospective study of obesity-related mortality, researchers explored US death trends before, during, and after the COVID-19 pandemic.

Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss how the role of PBMs in plan design is evolving.

Tara Pfund, PharmD, chief strategy officer with the Cascadia Pharmacy Group, discusses a variety of ways community pharmacists can expand services and support clinical reimbursement.

Abstract researchers explored whether or not a pharmacist could serve as the lead of a diabetes coaching program, aiming to reduce medical expenditures and A1C levels for at-risk patients.

John Hill, MBAHCM, and Pooja Babbrah, MBA, from the National Council for Prescription Drug Programs, discuss their organization’s strategic plan for advancing the pharmacy profession.

Morgan Lee, PhD, MPH, CPH, and Scott Halperin, PharmD, from the Pharmaceutical Strategies Group, discuss the 2025 Trends in Drug Benefit Design Report and how it will impact pharmacists.